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A B S T R A C T
Osteonecrosis of the jaw (ONJ) is a rare but serious drug induced adverse event, mainly associated with the use
of antiresorptive medications, such as intravenous (IV) bisphosphonates (BPs) in cancer patients. In this review,
we evaluated all the pharmacogenomic association studies for ONJ published up to December 2018. To date, two
SNPs (CYP2C8 rs1934951 and RBMS3 rs17024608) were identified to be associated with ONJ by two genome-
wide association studies (GWAS). However, all six subsequent candidate gene studies failed to replicate these
results. In addition, six discovery candidate gene studies tried to identify the genetic markers in several genes
associated with bone remodeling, bone mineral density, or osteoporosis. After evaluating the results of these 6
studies, none of the SNPs was significantly associated with ONJ. Recently, two whole-exome sequencing (WES)
analysis (including one from our group) were performed to identify variants associated with ONJ. So far, only
our study successfully replicated discovery result indicating SIRT1 SNP rs7896005 to be associated with ONJ.
However, this SNP also did not reach genome-wide significance. The major limitations of these studies include
lack of replication phases and limited sample sizes. Even though some studies had larger sample sizes, they
recruited healthy individuals as controls, not subjects treated with BPs. We conclude that a GWAS with a larger
sample size followed by replication phase will be needed to fully investigate the pharmacogenomic markers of
ONJ.
1. Introduction
Pharmacogenomics, or the genetic/genomic determinants of drug
response and adverse effects, is a tool that has been useful in in-
dividualizing medication therapy in order to improve drug efficacy and
minimize adverse effects [1,2]. Osteonecrosis of the jaw (ONJ) is a rare
but severe drug induced adverse event, which is defined as the exposure
of jaw bone (mandible, maxilla, or both) with slow healing for > 8
weeks, or even no healing [3]. ONJ was first reported in 2003 among
cancer patients treated with high doses of intravenous (IV) bispho-
sphonates (BPs) (pamidronate and zoledronate) [4]. Hence, the term
“Bisphosphonates Related Osteonecrosis of the Jaw” (BRONJ) was in-
itially used by the American Association of Oral and Maxillofacial
Surgeons (AAOMS) to describe this drug induced complication. In
2009, the term BRONJ was replaced with “Antiresorptive Related Os-
teonecrosis of the Jaw” (ARONJ) because another class of anti-
resorptive agents, receptor activator of nuclear factor kappa-B ligand
(RANKL) inhibitor, denosumab (Prolia®, Xgeva®) was found to be as-
sociated with ONJ [5]. Later in 2014, the term “Medication Related
Osteonecrosis of the Jaw” (MRONJ) was introduced in light of the fact
that antiangiogenic therapies were also linked to this complication [6].
For simplicity, we will use the term ‘ONJ’ in this review.
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2. Potential mechanisms of ONJ
Although many risk factors of ONJ have been identified, the me-
chanisms of ONJ is still not clear. Based on the different potential
mechanisms of ONJ development, three main hypotheses have been
proposed [6]. The first hypothesis involves bone remodeling inhibition
i.e. disruption of bone formation and bone resorption induced by os-
teoblasts and osteoclasts, respectively. Both BPs and RANKL inhibitor
(denosumab) are antiresorptive agents which interfere with the bone
resorption process. The second hypothesis is angiogenesis inhibition
which results in bone necrosis secondary to prevention of the formation
of new blood vessels in the bone. Bevacizumab, an angiogenesis in-
hibitor, has been reported to be associated with ONJ [7]. The third
hypothesis is inflammation and infection. Studies showed that most
ONJ patients had record of tooth extraction (~50%) [8–10]. Lots of
bacteria live in human mouth with gum disease and they likely induce
inflammation/infection after tooth extraction and lead to ONJ.
Even though increasing numbers of medication classes have been
reported to be associated with ONJ, antiresorptive agents still show the
highest risk for ONJ. Studies have shown that the average incidence of
ONJ was around 1.8% and 1.3% for denosumab and BPs, respectively,
but the difference was not significant [11,12]. The risk of ONJ in cancer
patients treated with IV BPs is ~10 times higher than that in osteo-
porosis patients based on the higher doses or more frequent adminis-
tration in cancer patients. The incidence rates of ONJ range from 0.8%
to 18% depends on oral or IV route of administration [12–14]. For this
review, we will focus on ONJ related to BPs since all the pharmaco-
genomic association studies for the ONJ phenotype were for BPs-related
ONJ.
BPs, as stable analogue of pyrophosphate, contain two phosphonate
groups with a central carbon. The chemical structure also contains one
short side chain (R1) and one long side chain (R2), which determine the
chemical properties of BPs. The BP structure creates high affinity for
hydroxyapatite binding sites on the bone surface [15]. BPs are in-
corporated into osteoclasts cells when the bone mineral is resorbed by
osteoclasts through bone remodeling [16–18]. After embedding into the
osteoclasts, BPs induce osteoclasts apoptosis that leads to inhibition of
bone resorption. Based on the difference in the structure of the R2 side
chain, BPs are divided into two classes: nitrogen containing BPs and
non‑nitrogen containing BPs. These two classes of BPs inhibit osteo-
clasts differentiation and induce osteoclasts apoptosis [19–21] through
different mechanisms. Nitrogen containing BPs, such as zoledronate
and pamidronate, inhibit bone resorption by binding and inhibiting
farnesyl pyrophosphate synthase (FPPS) in the HMGA-CoA reductase
pathway also known as mevalonate pathway [15,22]. This results in the
disruption of osteoclasts cytomembrane ruffles that lead to osteoclasts
apoptosis. On the other hand, non‑nitrogen containing BPs, such as
etidronate and clodronate are metabolized in the cells to compounds
that replace the pyrophosphate moiety from ATP to form a non-func-
tional molecule. The accumulation of non-functional molecules (toxic
analog of ATP) leads to inhibition of protein synthesis through com-
petition with ATP in mitochondria [23], which then induces apoptosis
in osteoclasts. Based on the effect on osteoclasts, BPs are used as anti-
resorptive agents for treatment and prevention of osteoporosis. Studies
have shown that BPs significantly decrease the risk of fractures and
increase bone mass density (BMD) in osteoporosis patients [12,24–26].
Given their non-proliferative action, BPs are important and effective
medications for preventing bone loss in cancer patients [15,21,27]
especially used for patients with multiple myeloma (MM) and other
cancers which metastasize to the bone, to prevent skeletal related
events (SREs) [28].
Metastasis is one of the main properties of cancer cell [29]. Most
cancers with metastases have high morbidity and mortality. Bone is the
third common site for the metastasis that is observed in MM and many
other solid cancers, such as breast, lung, and prostate cancers [30].
Previous studies have shown that cancer cells from breast and prostate
are most likely to migrate to bone during late-stage of these diseases
[31,32]. Based on the data from National Cancer Institute, almost 50%
of the breast and prostate cancer patients die due to bone metastases.
Bone metastasis occurring commonly in breast and prostate cancer re-
sults in the increase of osteoclasts cell growth and differentiation
[33,34]. The increasing osteoclastic activity leads to SREs, such as bone
pathological fractures and severe bone pain, which decreases the
quality of life of cancer patients.
The incidences of ONJ reported by European Association for Cranio-
Maxillo-Facial Surgery (EACMFS) and AAOMS are higher than those
reported in Japan [6,35,36]. MM shows a higher incidence in African-
American individuals, but ONJ cases in MM patients mostly occur in
those of European ancestry. Based on these, genetic factors likely con-
tribute to the development of ONJ. So far, multiple studies that have
been performed to assess the genetic determinants for ONJ [37–50].
This review evaluated all articles identifying genetic factors for ONJ
and recapitulated the current evidence on pharmacogenomics of ONJ.
3. Search strategy
Online literature searches were performed using PubMed databases
to retrieve the published studies. The search strategy was based on the
combination of the following separate terms: “genetic ONJ”, “phar-
macogenetics ONJ”, “pharmacogenomics ONJ”, “polymorphisms ONJ”,
“SNPs ONJ”, “GWAS ONJ”, “genome ONJ”, “exome ONJ” or “genome
wide ONJ”. These terms were serached again replacing “ONJ” with
“osteonecrosis of the jaw”.
4. Eligibility criteria
Literature was reviewed by two authors (GY, YC) independently.
Studies matching the following items were included: (1) Articles fo-
cusing on investigating the risk of ONJ; (2) Case control ONJ studies or
clinical studies comprising of baseline data; (3) Studies that included
genetic or SNPs analysis. Exclusion criteria were: (1) reviews or letters
about ONJ; (2) Studies that included ONJ but not genes or SNPs re-
search.
Based on the eligibility criteria, fifteen publications were included
in the review consisting of two genome-wide association study (GWAS)
[37,38], two whole exome sequencing analyses [39,40], and eleven
candidate gene studies [41–48,50–52] (Fig. 1).
5. Discovery candidate gene studies on ONJ
A total of six discovery candidate gene studies were published be-
tween 2010 and 2018 [43,46,47,50–52] (Table 1). These studies in-
vestigated the effects of variants in several genes, which had been se-
lected based on a potential role in BPs metabolism and/or ONJ
pathogenesis (e.g. bone turnover). Most of these studies genotyped only
a small number of variants and had small cohorts and are therefore
susceptible to limitations such as inadequate power. None of the single-
nucleotide polymorphisms (SNPs) tested in these studies reached sig-
nificance level after accounting for multiple comparisons.
The study by Di Martino et al [43] used Affymetrix DMET™ plus
platform [53], which genotyped a total of 1936 SNPs in 225 drug target
genes, to identify 8 SNPs with p-value < 0.05 located in 4 different
genes that are associated with development of ONJ (Table 1). This case-
control study comprised of 19 MM patient samples including 9 cases
suffering from ONJ induced by zoledronate and the other 10 MM pa-
tients were controls, who did not develop ONJ after treatment with
zoledronate. However, although this study genotyped total 1936 SNPs
which makes the Bonferroni corrected alpha as 2.5*10−5, none of 8
SNPs reached this alpha level. The top SNP rs1152003 was located on
PPARG (peroxisome proliferator-activated receptor gamma) gene with
the strongest p-value of 0.0064. PPARG is a compelling candidate gene
that is associated with bone remodeling [54–57], and is involved in
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decreasing osteoblasts and increasing osteoclasts differentiation. Even
though this gene is a strong candidate for bone remodeling, the SNP
located at PPARG needs to be further replicated in other independent
studies.
The study by Arduino et al [50] included 30 breast cancer or MM
female patients with ONJ as cases, 30 breast cancer or MM women
without ONJ as controls. All these 60 patients were treated with zole-
dronate (mean of duration therapy: 17.1(cases) and 11.4 (controls)
months, respectively). This study also included 125 unrelated healthy
volunteers as healthy controls. Because BPs have the ability to inhibit
angiogenesis [58], the investigators hypothesized that vascular en-
dothelial growth factor (VEGF) may play an important role in devel-
opment of ONJ. Previous studies have identified 3 common functional
SNPs in VEGF (rs2010963, rs3025039, and rs699947) [59–61]. The aim
of this study was to test the effect of these 3 SNPs in VEGF gene on ONJ.
This study compared ONJ cases with BPs tolerant control or healthy
controls, respectively. Upon analysis, none of these three SNPs was
associated with ONJ development. However, the haplotype AC de-
termined by two SNPs rs2010963 and rs699947 was significantly as-
sociated with ONJ (corrected p-value = 0.024).
Studies have shown that estrogen plays an important role in bone
remodeling by inhibiting osteoclasts formation and differentiation [62].
Estrogen also increases the inhibitory activity of BPs on osteoclasts
[63], thereby inducing osteoclasts apoptosis. Based on these findings,
La Ferla, et al postulated that estrogen may be associated with devel-
opment of ONJ [52]. To test this hypothesis, they genotyped two es-
trogen SNPs (rs2234693 and rs9340799) and one aromatase SNP
(rs10046) using Taqman genotyping assay. Aromatase, also named es-
trogen sythetase, play a key role in the biosynthesis of estrogen. This
study included 20 ONJ cases and 53 controls. All samples were MM or
patients with metastatic cancer and treated with zoledronate. Results
showed that the aromatase SNP, rs10046, was significantly associated
with development of ONJ (p = 0.0439, OR = 2.83).
Marini F, et al showed that the FDPS intronic region SNP rs2297480
C allele showed lower response to serum osteocalcin by amino-bi-
sphosphonate therapy [64]. FDPS is farnesyl diphosphate synthase
gene, which encodes a key enzyme of the mevalonate pathway. Studies
have shown that FDPS plays a vital role in the mechanism by which BPs
affect osteoclasts survival [21,65,66]. They thus tested rs2297480 SNP
in the FDPS gene in 68 Caucasian MM or metastatic cancer patients who
received zoledronate treatment (34 ONJ cases and 34 non-ONJ
controls) [51]. This study showed FDPS intronic region SNP,
rs2297480, was significantly associated with ONJ with a p-value of
0.03.
Katz et al [46] investigated 10 SNPs in 7 candidate genes (CYP2C8,
COL1A1, RANK, OPN, MMP2, OPG and TNF) in total 78 MM patients
treated with zoledronate and/or pamidronate, including 12 ONJ cases
and 66 non-ONJ controls. All 7 genes were selected because they were
associated with bone remodeling, BMD, or osteoporosis. Upon analysis,
none of these SNPs were associated with ONJ (all p-values > 0.05).
However, this study constructed genotype scores for 5 candidate gene
(OPG, COL1A1, RANK, MMP2, and OPN) to study the potential com-
bined effect of all five SNPs located in these genes. Genotype score is a
method to estimate multiple SNPs or genes effects on complex diseases
[67,68]. For this study, the combined genotype of OPG, COL1A1,
RANK, MMP2, and OPN was significantly associated with ONJ devel-
opment with p-value = 0.0097 (OR: 11.2; 95% confidence interval (CI):
1.8–69.9).
Several clinical studies and animal studies have demonstrated that
inflammation/infection is associated with ONJ development [69–72].
Major histocompatibility complex (MHC) class II molecules are im-
portant in immune responses, and one study has shown that mice with
MHC class II deficiency were more susceptible to infection [73]. The
study of Stockmann et al [47] conducted so far the largest discovery
candidate gene study to investigate the effect of the SNPs of MHC class
II on ONJ development. Total 204 MM or malignant cancer participants
treated with BPs were recruited, including 94 ONJ cases and 110 non-
ONJ controls. After Bonferroni correction, HLA haplotype DRB*15-
DQB1*06:02 (p-value = 0.032, OR 2.5, 95% CI 1.3–5.0), was sig-
nificantly associated with ONJ development. Moreover, DRB1*01H
and/or DRB1*15H (p-value = 0.0003, OR 3, 95% CI 1.7–5.5) were
even more significantly associated with ONJ.
6. Genome-wide association studies (GWAS) on ONJ
GWAS is a method for researchers to identify genetic variants as-
sociated with risk of disease or drug response to medications. GWAS
evaluate the entire genome for genetic polymorphisms and sequence
SNPs based on the linkage disequilibrium (LD). As of the time of writing
of this review, only two GWASs of ONJ have been published [37,38]
(Table 2). The study of Sarasquete et al [37] was the first GWAS on the
phenotype of ONJ. This study included 87 MM patients (22 cases and
Fig. 1. Flow diagram for the article selection process.

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































G. Yang, et al. Bone 124 (2019) 75–82
78
65 controls) treated with pamidronate or zoledronate. This study
identified 4 CYP2C8 SNPs (rs1934951, rs19934980, rs1341162 and
rs17110453) to be associated with ONJ. However, only one SNP,
rs1934951, showed a significant association with ONJ development
after the Bonferroni correction (corrected p-value = 0.02). T allele of
this SNP showed a higher risk of ONJ development with OR of 12.75
(95% CI: 3.7–43.5). CYP2C8 enzyme plays an important role in drug
metabolism and synthesis of cholesterol, steroids and other lipids [74].
So far, the underlying mechanism of the association of CYP2C8 with the
development of ONJ is still not clear.
Another GWAS was published in 2012 by Nicoletti et al [38]. This
study included 30 breast cancer patients who developed ONJ after
treatment with zoledronate as cases, and 17 breast cancer patients who
did not develop ONJ after treatment with BPs, as the control group. In
addition, this study included 1726 healthy population controls to in-
crease the power. A RBMS3 gene SNP, rs17024608, was identified to be
significantly associated with ONJ (p-value: 7.47*10−8, OR = 5.8, 95%
CI: [3.0–11.0]). This study further showed that there was an interaction
between RBMS3 and ZNF516 which affects bone mineral density [75].
RBMS3 encodes an RNA-binding protein, which is associated with up-
regulation of collagen type I [76], which an important component of
the bone matrix.
Lack of replication was the biggest limitation of both these studies.
Moreover, both of these studies had limited sample sizes and the p-
value for GWAS did not reach genome-wide significance level of
5*10−8.
7. Replication studies
So far, five candidate gene studies have attempted to replicate the
results of GWAS of Sarasquete ME, et al [41,42,45,46,48] (Table 3).
These studies investigated the effect of CYP2C8 SNP, rs1934951, on the
development of ONJ in other independent cohorts. All five studies
failed to demonstrate significant association between SNP rs1934951
and ONJ development (p-value > 0.05). Balla B, et al investigated the
effect of CYP2C8 rs1934951 on ONJ development in 270 Hungarian
subjects, including 46 ONJ cases and 224 healthy unrelated Hungarian
controls. Their study showed SNP rs1934951 to be significantly asso-
ciated with the localization of ONJ among the affected patients (p-
value < 0.05). Heterozygous genotype A/G of this SNP had the higher
risk for mandibular ONJ as compared to the maxilla or both locations
together. Homozygote G/G showed no significant difference ONJ lo-
calization. However, this study did not show association between this
SNP and ONJ development. Kastritis et al [45] genotyped CYP2C8 SNP
rs1934951 in 140 subjects treated with zoledronate, including 36 ONJ
cases and 104 controls. This study showed no significant difference
between ONJ cases and non-ONJ controls for the allele frequency this
SNP. However, this study found that the dose of zoledronate was as-
sociated with ONJ development. Higher dose of zoledronate was as-
sociated with higher risk of ONJ development. Longer use of zole-
dronate was associated with higher risk for ONJ development. This
study also attempted to replicate the result of Di Martino et al [43] by
genotyping the PPARG gene SNP rs1152003. This SNP also showed no
significant association with ONJ. The study of Katz et al [46] failed to
show that CYP2C8 SNP rs1934951 was associated with ONJ develop-
ment in 78 MM patients (p-value = 0.63). English et al [41] failed to
replicate the result of first GWAS performed by Sarasquete ME, et al. in
prostate cancer patients with p-value > 0.47 (OR = 0.63, 95% CI:
0.165–2.42). Such et al [42] tried to use similar samples and medica-
tion conditions as the study by Sarasquete ME, et al to replicate the
effect of CYP2C8 SNP rs1934951 on ONJ development, but they also
failed to replicate this association.
Another replication candidate gene study focused on VEGF gene was
published by Choi H, et al in 2015 [44]. This study genotyped VEGF
SNPs rs699947, rs2010963, and rs3025039 in a total of 45 patients (26
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rs2010963 were nominally associated with ONJ development
(p = 0.04, p = 0.03, respectively). However the haplotype AC de-
termined by two SNPs rs2010963 and rs699947 was not significantly
associated with ONJ (p = 0.126), even though these two SNPs have
high LD (r2 = 0.96).
There are some potential reasons for the failure of the replication
efforts. Firstly, there were differences in the population that was used
for replication in the candidate gene studies. The first GWAS by
Sarasquete ME, et al was conducted in individuals of Spanish ancestry
whereas none of other replication efforts used subjects of Spanish an-
cestry, even though some studies used European patients. Secondly, the
GWAS was conducted in MM patients treated with zoledronate and/or
pamidronate. However, only two of the replication studies focused on
MM patients. Moreover, subjects in these two studies were treated with
zoledronate only.
The discovery candidate gene study for VEGF used patients of
European ancestry, but replication effort for this gene was undertaken
using patients of Korean ancestry. HaploReg v4.1 [77] shows that the
LD (r2) for SNP rs699947 and rs2010963 is 0.45 in Europeans, but 0.96
in Asians.
8. Whole-exome sequencing analysis
Whole-exome sequencing (WES) determines the sequence of all
protein-coding genes in human genome. This method covers < 2% of
human genome, but contain > 85% of known disease-related variants
[78]. Based on above mentioned, WES is a cost-effective alternative to
whole-genome sequencing.
So far, two WES studies have been published [39,40] (Table 4). Kim
et al [40] identified four genes (ARSD, SLC25A5, CCNYL2, and PGYM)
associated with ONJ with the lowest p-value (p-value < 0.05) using
WES and Gene set enrichment analysis (GSEA) methods. GSEA is a
computational method that investigates genetic variants in a group of
genes to elucidate the gene differences between cases and controls. This
was the first study that combined WES and GSEA methods to in-
vestigate the function of SNPs between ONJ patients and non-ONJ
participants.
The WES from our group [39] was the first study that performed
both discovery and replication followed by meta-analysis so far.
Moreover, our study included not only MM but also other metastatic
solid cancers as cases and controls. The meta-analysis identified SIRT1
SNP rs7896005 and HERC4 SNP rs3758392 to be associated with ONJ
with the lowest p-value (3.9*10−7) approaching genome-wide sig-
nificance. The HERC4 SNP rs3758392 had the same p-value as
rs7896005 because of high LD (r2 = 0.88). These two SNPs were both
expression quantitative loci (eQTLs) for SIRT1. SIRT1 was a very
compelling candidate gene of bone remodeling. Studies had shown that
SIRT1 plays a vital role in bone remodeling by affecting the Wnt sig-
naling pathway [79–82] and RANK/RANKL/OPG pathway [83,84].
9. Conclusion
ONJ is a rare but serious drug induced adverse event, which criti-
cally increases discomfort and reduces quality of life in patients. Studies
have shown that the risk of ONJ development is higher in patients of
European ancestry than other populations [12,14,85]. Investigators
believe that genetic factors play an important role in ONJ development.
Candidate gene studies have focused on investigating the association
between genetic variations within certain genes of interest and ONJ.
However, the selection of candidate genes is limited by priori knowl-
edge. WES approach identifies potentially functional genetic variations
through sequencing protein-code region of genes in the human genome.
Table 3
Summary of replication candidate gene studies for ONJ.
Authors Population Disease BPS Cases/
controls
(N)
SNPS Genes P-value OR (95% CI) Function









Prostate cancer Zoledronate 17/83 rs1934951 CYP2C8 > 0.05 0.63 (0.165–2.42) Intronic
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BPs: bisphosphonates; OR: odds ratio; 95% CI: confidence interval.
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However, since it only cover < 3% of human genome, WES may also
miss the important genetic markers that are potentially associated with
ONJ. Even though GWAS surveys the entire genome, it requires larger
sample sizes and replication phase. So far, none of the genetic poly-
morphisms reported in the ONJ GWAS studies have been replicated,
largely due to limited sample size and lack of validation. In summary,
after reviewing the ONJ Pharmacogenomics literature, no genetic
markers for ONJ have been replicated or functionally validated. We
conclude that a GWAS with larger sample size followed by replication
and functional validation will be needed to fully investigate the phar-
macogenomics of ONJ.
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